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To the Editor: I read with interest the case of primary
aldosteronism (PA) presented by Chen et al.1 The clinical course,
resolution of hypokalemia and hypertension by right adrena-
lectomy, and the pathological finding, a cortical microadenoma
in the resected adrenal gland, support their diagnosis of
aldosterone-producing adenoma of the right adrenal gland.
However, I would like to comment about a potential pitfall in
the usage of 131I-6-beta-iodomethylnorcholesterol (131I-NP-59)
to detect the origin of aldosterone hypersecretion in PA.
The unilateral uptake of 131I-NP-59 under dexamethasone
suppression in PA could indicate aldosterone hypersecre-
tion from the side with the uptake. However, cases of
false-positive unilateral uptake in hyperplasia and cases of false
negative localizations (bilateral positive, bilateral negative, and
incorrect side-positive) in aldosterone-producing adenoma
have been reported.2,3 Therefore, the 131I-NP-59 uptake would
not properly indicate the side of aldosterone hypersecretion in
some cases of PA. Adrenal vein sampling (AVS) is now
considered the most reliable test for detecting the side of
aldosterone hypersecretion in PA.4 The treatment for PA, either
adrenalectomy or medical treatment with a mineralocorticoid
receptor antagonist, should be based on the result of AVS.
1. Chen YC, Wei CK, Chen PF et al. Seeking the invisible: I-131 NP-59 SPECT/
CT for primary hyperaldosteronism. Kidney Int 2009; 75: 663.
2. Gross MD, Shapiro B, Freitas JE. Limited significance of asymmetric
adrenal visualization on dexamethasone-suppression scintigraphy. J Nucl
Med 1985; 26: 43–48.
3. Glodny B, Kuhle C, Cromme S et al. An assessment of diagnostic
procedures preparatory to retroperitoneoscopic removal of adenoma in
cases of primary hyperaldosteronism. Endocr J 2000; 47: 657–665.
4. Funder JW, Carey RM, Fardella C et al. Case detection, diagnosis, and
treatment of patients with primary aldosteronism: an endocrine society
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We heartily thank Dr Tanemoto1 for the interest in our
article.2 We agree that traditional planar adrenal scinti-
graphy with NP-59 and dexamethasone suppression has
low sensitivity and specificity and cannot detect adenomas
o1 cm in diameter. Despite the high adrenal avidity of NP-
59, the computer hardware provides limited resolution and
does not allow detection of early adrenal activity.3
Single-photon emission computed tomography
(SPECT) provides spatial and quantitative data on
adrenocortical uptake and allows detection of smaller
lesions.4,5 In NP-59 SPECT, the hallmark of diagnosis is
early visualization before the fifth post-injection day.4 The
unilateral uptake signifies either frequent unilateral
adrenal adenoma, or rare unilateral adrenal hyperplasia,
both of which are surgically curable.6 SPECT/CT, which
uses an integrated dual-head gamma camera and a CT
scanner, provides functional and anatomical imaging in
one session, allows accurate localization of tumors, and
enhances the accuracy of SPECT, all of which may affect
clinical decision making.7 Higher levels of sensitivity,
specificity, positive predictive value, and negative predic-
tive value can be attained by performing SPECT/CT with
high-end CT.8
In our case, CT alone provided no evidence of a lesion,
and traditional planar NP-59 scintigraphy alone indicated
no uptake of radioactivity. However, radioactivity was
evident after SPECT imaging, and this was localized by
SPECT/CT. We did not use adrenal venous sampling
because this method is invasive, is associated with
various risks (even when performed by an experienced
expert), and because of difficulty in approaching the right
adrenal vein.9
By performing NP-59 SPECT/CT, we identified a
cortical micronodule that was 815 lm in diameter, the
smallest adenoma identified in a pathological examination
at present. NP-59 SPECT/CT is a significant technical
innovation that provides a noninvasive and promising
alternative for the diagnosis of subtle primary hyperaldos-
teronism when there is a high clinical suspicion despite a
negative confirmation test and negative CT scan.
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To the Editor: Cukor et al.1 very recently showed that dialysis
patients were more depressed and had lower adherence to
medication when compared with patients with renal
transplantation. In addition, they found that lack of
adherence to medical treatments is independently associated
with depressive behavior as determined by the Beck
Depression Inventory.
Previously we have observed very similar results in
hemodialysis patients, although our study differs from the
study by Cukor et al. in some methodological aspects.2 We
have shown that among 86 hemodialysis patients who were
on the renal transplantation waiting list, 49 were nonadher-
ent. In our study, clinical nonadherence was defined as
skipping or shortening of dialysis sessions, interdialytic
weight gain of 45.7% of body weight, a predialysis
potassium level of 46mEq/l, and a predialysis phosphorus
level of47.5mg per 100ml. We recorded sociodemographic
and laboratory parameters. We also evaluated quality of life
(by the SF-36) and depressive behavior by the Beck
Depression Inventory. Although nonadherent patients had
lower quality of life, and higher Beck Depression Inventory
scores, nonadherence was associated only with Beck Depres-
sion Inventory scores in our study (odds ratio: 2.146;
confidence interval: 2.052–2.350; P: 0.002).2
Nonadherence in dialysis patients was associated with
increased mortality.3 On the other hand, depression was
considered the most common psychopathology among
dialysis patients.4 In light of Cukor et al.’s and our findings,
we suggest that depression may be one of the permissive
factors for nonadherent behavior in dialysis patients and thus
related with increased mortality. In addition, treatment of
depression may improve adherence. Longitudinal studies are
needed to highlight these issues.
1. Cukor D, Rosenthal DS, Jindal RM et al. Depression is an important
contributor to low medication adherence in hemodialyzed patients and
transplant recipients. Kidney Int 2009; 75: 1223–1229.
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We thank Drs Afsar and Akman for their letter.1 We are
gratified that our study2 had results similar to their
findings3 even though the populations were quite
different, as this shows the robustness of the relationship
between nonadherence and depression. In further analyses
of our data, we identified social support4 as significantly
associated with medication adherence (r¼ 0.28,
Po0.05) and depression (r¼0.40, Po0.001). In our
exploratory model, depression emerged as a mediator,
suggesting that the relationship between social support
and medication adherence is attenuated through depres-
sive affect.
The scientific study of nonadherence in end-stage
renal disease (ESRD) populations is still in its infancy.
The field lacks a standard assessment strategy or even an
identified minimum threshold of adherence required to
prevent complications. The studies thus far have been
correlational in design; therefore, the direction of the
relationships is undetermined. However, as depression is a
common comorbidity,5 all ESRD patients should be
carefully screened for depression and treatment
regimen adherence. Similarly, interventions to promote
treatment adherence should address the level of depressive
affect. Controlled trials to treat depression in ESRD
are needed, as untreated depression may contribute
directly, or be mediated through nonadherence, to poor
outcomes. These studies should include objective assess-
ments of depression and measure multiple outcomes,
including the effect of psychological therapy on depres-
sion, quality of life, adherence, laboratory values, and
mortality.
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